Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR
Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...

Associated Conditions
Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Associated Therapies
-
Clinical Trials
Related News

Ziprasidone And Olanzapine's Outcomes In Mania

First Posted Date
2006-05-24
Last Posted Date
2021-03-29
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
29
Registration Number
NCT00329108
Locations
🇹🇷

Pfizer Investigational Site, Istanbul, Turkey

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

First Posted Date
2006-05-03
Last Posted Date
2012-01-23
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
524
Registration Number
NCT00320489
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan City, Taiwan

Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Olanzapine
First Posted Date
2006-02-10
Last Posted Date
2013-03-14
Lead Sponsor
Université de Montréal
Target Recruit Count
25
Registration Number
NCT00290121
Locations
🇨🇦

Centre de recherche Fernand-Seguin, Montréal, Quebec, Canada

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

First Posted Date
2006-02-07
Last Posted Date
2011-07-25
Lead Sponsor
Nathan Kline Institute for Psychiatric Research
Target Recruit Count
46
Registration Number
NCT00287820
Locations
🇺🇸

Manhattan Psychaitric Center, New York, New York, United States

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

Not Applicable
Completed
Conditions
Borderline Personality Disorder
Interventions
Drug: olanzapine
First Posted Date
2006-01-11
Last Posted Date
2017-05-23
Lead Sponsor
University of Minnesota
Target Recruit Count
19
Registration Number
NCT00275301
Locations
🇺🇸

University of Minnesota, Dept of Psychiatry, Minneapolis, Minnesota, United States

Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial

Phase 3
Withdrawn
Conditions
Therapy-resistant Depression
Interventions
Drug: Placebo
Drug: Olanzapine
First Posted Date
2006-01-09
Last Posted Date
2022-08-10
Lead Sponsor
University Hospital Freiburg
Registration Number
NCT00273624
Locations
🇩🇪

Dept. of Psychiatry, University of Freiburg, Freiburg, Germany

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

First Posted Date
2005-12-19
Last Posted Date
2010-12-28
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
139
Registration Number
NCT00266630
Locations
🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: asenapine
Drug: olanzapine
First Posted Date
2005-12-14
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
306
Registration Number
NCT00265343

Olanzapine in the Treatment of Patients With Anorexia Nervosa

Phase 2
Completed
Conditions
Anorexia Nervosa
Interventions
Drug: Olanzapine
Behavioral: Day Hospital
First Posted Date
2005-12-02
Last Posted Date
2018-01-30
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
34
Registration Number
NCT00260962
Locations
🇨🇦

Ottawa Hospital, Ottawa, Ontario, Canada

SB-773812 Administered In Adults With Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
First Posted Date
2005-12-01
Last Posted Date
2017-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
338
Registration Number
NCT00259870
Locations
🇷🇺

GSK Investigational Site, St.Petersburg, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy